An innovative skin cancer treatment that combines immunotherapy with mRNA vaccine technology has shown promising results in a recent advanced trial, as stated in a joint news release by pharmaceutical companies Merck and Moderna on Wednesday.
The new treatment, named intismeran, outperformed immunotherapy alone in reducing melanoma recurrence and preventing cancer spread to other body parts in patients who had undergone prior melanoma surgery.
Although the Phase 3 trial is ongoing and the disclosed results are from an interim analysis, healthcare professionals have expressed cautious optimism about the findings. Dr. Marcus Butler, a medical oncologist at Toronto’s Princess Margaret Cancer Centre, described the announcement as a positive development for the field, citing the encouraging outcomes of the Phase 2 study.
The treatment, combining Merck’s pembrolizumab immunotherapy drug (Keytruda) with a personalized mRNA vaccine from Moderna, utilizes tumor samples to target abnormal proteins in cancer cells known as neoantigens. This approach aims to train the immune system to recognize and attack cancer cells carrying these antigens.
While awaiting comprehensive trial data confirmation, experts emphasize the logistical and operational challenges of scaling up this novel treatment globally. Dr. Ramy Saleh from McGill University highlighted the importance of addressing cost concerns and garnering support from taxpayers and governments for widespread adoption.
The trial, which involved 1,137 high-risk patients with surgically removed Stage IIB-IV melanoma, included Canadian participants. Volunteers were randomly assigned to receive Keytruda with the personalized vaccine or Keytruda alone for approximately a year. No new safety issues were reported during the trial.
Dr. Butler raised a potential concern regarding mRNA vaccine-induced immune stimulation, which could impact the interpretation of trial results. He also noted that the current study focused on early-stage melanoma patients with completely excised tumors, underscoring the need for further research in advanced-stage cases.
While acknowledging the promising early-stage results, experts emphasized the necessity of additional studies to assess the treatment’s efficacy in later-stage melanoma patients. Ongoing clinical trials are investigating this approach, considering past trials that have yielded unfavorable outcomes in different patient populations.
In conclusion, the collaborative efforts of Merck and Moderna in developing this innovative skin cancer treatment have shown promising initial results, signaling a potential breakthrough in melanoma therapy.